Table:
Phenotype and functionality of the infusion products	Clinical outcome
Patient number	Infused cells	CD8+	CD45RO+	CCR7+	CD27+	Reactivitya	Total number of responding CD8+T cells infused	Response	TTP	OS
(x 1010)	(%)	(%)	(%)	(% of CD8)	(%)	(x 106)	(RECIST)	(mo)	(mo)
1	2.9	94	99.7	7.5	6.1	28.8#	6460	CR	30+	30+
2	1.8	92	97.4	4.9	5.2	1.0#	175	PD	2	7
3	2.0	95	99.4	6.1	0.5	0.0#	7	SD	4	11.5
6	0.3	47	98.4	3.9	1.2	0.9*	41	PD	2	4.6
7	1.3	88	89	31.8	3.4	0.4#	44	SD	5	11
11	7.5	95	99	0.6	8.1	6.0*	4377	CR	10+	10+

Parse the following content of the figure in markdown code: |  | <COLSPAN=7> Phenotype and functionality of the infusion products | <COLSPAN=3> Clinical outcome | 
 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | 
 | Patient number | Infused cells | CD8+ | CD45RO+ | CCR7+ | CD27+ | Reactivitya | Total number of responding CD8+T cells infused | Response | TTP | OS | 
 |  | (x 1010) | (%) | (%) | (%) | (% of CD8) | (%) | (x 106) | (RECIST) | (mo) | (mo) | 
 | 1 | 2.9 | 94 | 99.7 | 7.5 | 6.1 | 28.8# | 6460 | CR | 30+ | 30+ | 
 | 2 | 1.8 | 92 | 97.4 | 4.9 | 5.2 | 1.0# | 175 | PD | 2 | 7 | 
 | 3 | 2.0 | 95 | 99.4 | 6.1 | 0.5 |

0.0# | 7 | SD | 4 | 11.5 | 
 | 6 | 0.3 | 47 | 98.4 | 3.9 | 1.2 | 0.9* | 41 | PD | 2 | 4.6 | 
 | 7 | 1.3 | 88 | 89 | 31.8 | 3.4 | 0.4# | 44 | SD | 5 | 11 | 
 | 11 | 7.5 | 95 | 99 | 0.6 | 8.1 | 6.0* | 4377 | CR | 10+ | 10+ |